Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Preliminary In Vitro Interaction of ET-26-HCl With Human Serum Albumin Through Rapid Equilibrium Dialysis Under Simulated Physiological Conditions.

Biomedical chromatography : BMC·2026
Same author

Remimazolam provides better hemodynamic stability than propofol in hypertensive surgical patients: a randomized single-blinded trial.

Journal of anesthesia·2025
Same author

Frailty and Anemia in Geriatric Care: A Retrospective Cohort Study.

The American journal of nursing·2025
Same author

Bile Acid-based Microcapsule-Like Cocrystals of Phytosterols with Enhanced Solubility, Bioavailability, and Bioactivity.

Molecular pharmaceutics·2025
Same author

IL-33-Induced TREM2<sup>+</sup> Macrophages Promote Pathological New Bone Formation Through CREG1-IGF2R Axis in Ankylosing Spondylitis.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Supplementation with Lentil (<i>Lens culinaris</i>) Hull Soluble Dietary Fiber Ameliorates Sodium Dextran Sulfate-Induced Colitis and Behavioral Deficits via the Gut-Brain Axis.

Foods (Basel, Switzerland)·2025

Related Experiment Video

Updated: Aug 29, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

573

Neoadjuvant Therapy for Hepatocellular Carcinoma.

Zongyi Yin1,2,3, Dongying Chen3,4, Shuang Liang1

  • 1Department of Hepatobiliary Surgery, Shenzhen University General Hospital, Shenzhen University, Shenzhen, 518055, People's Republic of China.

Journal of Hepatocellular Carcinoma
|September 7, 2022
PubMed
Summary

Neoadjuvant therapy (NAT) shows promise for improving outcomes in hepatocellular carcinoma (HCC) treatment, despite current strategies falling short. Future research should focus on biomarkers, resistance mechanisms, and standardized endpoints for NAT in HCC.

Keywords:
HCCchemotherapyhepatocellular carcinomaimmunotherapyneoadjuvant therapysystemic therapy

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.4K

Related Experiment Videos

Last Updated: Aug 29, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

573
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.4K

Area of Science:

  • Hepatobiliary Cancers
  • Oncology
  • Surgical Oncology

Background:

  • Hepatocellular carcinoma (HCC) presents challenges with low surgical resection rates and high recurrence.
  • Existing treatments for HCC are insufficient to meet clinical demands.
  • Neoadjuvant therapy (NAT) is a standard approach for other solid tumors, improving resectability and reducing recurrence.

Purpose of the Study:

  • To evaluate the current status and future potential of neoadjuvant therapy (NAT) in hepatocellular carcinoma (HCC) management.
  • To highlight the growing evidence supporting NAT for HCC.
  • To identify key areas for future research in NAT for HCC.

Main Methods:

  • Review of current literature on neoadjuvant therapy in solid tumors and HCC.
  • Analysis of emerging evidence regarding systemic therapies (targeted therapy, immunotherapy) in HCC.
  • Discussion of challenges and future directions for NAT in HCC.

Main Results:

  • Neoadjuvant therapy (NAT) is not yet standardized for HCC, with ongoing debate on its efficacy.
  • Systemic therapies, including targeted therapy and immunotherapy, are increasingly used in HCC.
  • Evidence suggests NAT is becoming a viable option for HCC treatment.

Conclusions:

  • Neoadjuvant therapy (NAT) holds significant potential for improving outcomes in hepatocellular carcinoma (HCC).
  • Future research must prioritize identifying predictive biomarkers for NAT response.
  • Investigating resistance mechanisms and standardizing endpoints are crucial for advancing NAT in HCC.